Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DW01LJ
|
|||
| Drug Name |
CLT030
|
|||
| Drug Type |
Antibody drug conjugate
|
|||
| Indication | Acute myeloid leukaemia [ICD-11: 2A60; ICD-9: 205] | Phase 1 | [1] | |
| Company |
Cellerant Therapeutics
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Myeloid inhibitory C-type lectin-like receptor (CD371) | Target Info | . | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | CLT030, a leukemic stem cell-targeting CLL1 antibody-drug conjugate for treatment of acute myeloid leukemia. Blood Adv. 2018 Jul 24;2(14):1738-1749. | |||
| REF 2 | Clinical pipeline report, company report or official report of Cellerant Therapeutics. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.